Frleta D, Ochoa CE, Kramer HB, Khan SA, Stacey AR, Borrow P, Kessler BM, Haynes BF, Bhardwaj N. HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest. 2012 Dec 3; 122(12): 4685-97. Abstract

Baalwa J, Wang S, Parrish NF, Decker JM, Keele BF, Learn GH, Yue L, Ruzagira E, Ssemwanga D, Kamali A, Amornkul PN, Price MA, Kappes JC, Karita E, Kaleebu P, Sanders E, Gilmour J, Allen S, Hunter E, Montefiori DC, Haynes BF, Cormier E, Hahn BH, Shaw GM. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology. 2013 Feb 5;436(1):33-48. Abstract

Song H, Pavlicek JW, Cai F, Bhattacharya T, Li H, Iyer SS, Bar KJ, Decker JM, Goonetilleke N, Liu MK, Berg A, Hora B, Drinker MS, Eudailey J, Pickeral J, Moody MA, Ferrari G, McMichael A, Perelson AS, Shaw GM, Hahn BH, Haynes BF, Gao F. Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology. 2012 Oct 30; 9:89. Abstract

Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza For The Moph Taveg Collaboration MS. The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Res Hum Retroviruses. 2012 Oct 4. [Epub ahead of print] Abstract

Haynes BF, Permar S. A tribute to Norman L. Letvin (1949–2012). J Clin Invest. 2012 Aug 1; 122(8): 2709-10. No abstract available.

Bonsignori M, Alam SM, Liao HX, Verkoczy L, Tomaras GD, Haynes BF, Moody MA. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol. 2012 Sep 13. pii: S0966-842X(12)00156-4. Abstract

Parrish NF, Wilen CB, Banks LB, Iyer SS, Pfaff JM, Salazar-Gonzalez JF, Salazar MG, Decker JM, Parrish EH, Berg A, Hopper J, Hora B, Kumar A, Mahlokozera T, Yuan S, Coleman C, Vermeulen M, Ding H, Ochsenbauer C, Tilton JC, Permar SR, Kappes JC, Betts MR, Busch MP, Gao F, Montefiori D, Haynes BF, Shaw GM, Hahn BH, Doms RW. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog. 2012; 8(5): e1002686. Abstract

Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012 Aug 1; 206(3): 431-41. Abstract

Doria-Rose NA, Georgiev I, O'Dell S, Chuang GY, Staupe RP, McLellan JS, Gorman J, Pancera M, Bonsignori M, Haynes BF, Burton DR, Koff WC, Kwong PD, Mascola JR. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol. 2012 Aug; 86(15): 8319-23. Abstract

Yaming Wang, Melissa Swiecki, Marina Cella, Gottfried Alber, Robert D. Schreiber, Susan Gilfillan, Marco Colonna, Timing and Magnitude of Type I Interferon Responses by Distinct Sensors Impact CD8 T Cell Exhaustion and Chronic Viral Infection, Cell Host & Microbe, Volume 11, Issue 6, 14 June 2012, Pages 631-642. Abstract

Nancie M. Archin, Naveen K. Vaidya, JoAnn D. Kuruc, Abigail L. Liberty, Ann Wiegand, Mary F. Kearney, Myron S. Cohen, John M. Coffin, Ronald J. Bosch, Cynthia L. Gay, Joseph J. Eron, David M. Margolis, and Alan S. Perelson. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. PNAS. 2012 ; published ahead of print May 29, 2012. Abstract

Friedman J, Alam SM, Shen X, Xia S-M, Stewart S, et al. Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum. PLoS One. 7(5): e37648. Full Text

Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M; the CHAVI 001 clinical team, Dersimonian R, Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori DC, Sibeko S, Soderberg K, Tomaras G, Yang ZY, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, Mascola JR. The Development of CD4 Binding Site Antibodies During HIV-1 Infection. J Virol. 2012 May 9. [Epub ahead of print] Abstract

Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012 May 7; 30(5): 423-33. Abstract

Moody MA, Yates NL, Amos JD, Drinker MS, Eudailey JA, Gurley TC, Marshall DJ, Whitesides JF, Chen X, Foulger A, Yu JS, Zhang R, Meyerhoff RR, Parks R, Scull JC, Wang L, Vandergrift NA, Pickeral J, Pollara J, Kelsoe G, Alam SM, Ferrari G, Montefiori DC, Voss G, Liao HX, Tomaras GD, Haynes BF. HIV-1 gp120 Vaccine Induces Affinity Maturation in Both New and Persistent Antibody Clonal Lineages. J Virol. 2012 May 2. [Epub ahead of print] Abstract

Freel SA, Picking RA, Ferrari G, Ding H, Ochsenbauer C, Kappes JC, Kirchherr J, Soderberg K, Weinhold KJ, Cunningham CK, Denny T, Crump JA, Cohen MS, McMichael AJ, Haynes BF, Tomaras GD. Initial HIV- 1 Antigen-specific CD8+ T cells In Acute HIV-1 Inhibit Transmitted Founder Virus Replication. J Virol. 2012 Apr 18. [Epub ahead of print] Abstract

McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol. 2012 Apr 18; 13(5): 423-7. Abstract

Hardy GJ, Lam Y, Stewart SM, Anasti K, Alam SM, Zauscher S. Screening the interactions between HIV-1 neutralizing antibodies and model lipid surfaces. J Immunol Methods. 2012 Feb 28; 376(1-2):13-9. Abstract

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. N Engl J Med 2012; 366:1275-1286. Abstract

Bonsignori M, Montefiori DC, Wu X, Chen X, Hwang KK, Tsao CY, Kozink DM, Parks RJ, Tomaras GD, Crump JA, Kapiga SH, Sam NE, Kwong PD, Kepler TB, Liao HX, Mascola JR, Haynes BF. Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-infected Donor: Implications for Vaccine Design. J Virol. 2012 Feb 1. [Epub ahead of print] Abstract

Riou C, Ganusov VV, Campion S, Mlotshwa M, Liu MK, Whale VE, Goonetilleke N, Borrow P, Ferrari G, Betts MR, Haynes BF, McMichael AJ, Gray CM. Distinct Kinetics of Gag-Specific CD4+ and CD8+ T Cell Responses during Acute HIV-1 Infection. J Immunol. 2012 Mar 1;188(5):2198-206. Epub 2012 Jan 27. Abstract

Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG, Salazar-Gonzalez JF, Shattock R, Haynes BF, Shaw GM, Hahn BH, Kappes JC. Generation of Transmitted/Founder HIV-1 Infectious Molecular Clones and Characterization of Their Replication Capacity in CD4 T Lymphocytes and Monocyte-Derived Macrophages. J Virol. 2012 Mar;86(5):2715-28. Abstract

Hwang KK, Chen X, Kozink DM, Gustilo M, Marshall DJ, Whitesides JF, Liao HX, Catera R, Chu CC, Yan XJ, Luftig MA, Haynes BF, Chiorazzi N. Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells. Blood. 2012 Feb 16;119(7):e35-44. Abstract

Lavine CL, Lao S, Montefiori DC, Haynes BF, Sodroski JG, Yang X; the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). High-Mannose Glycan-Dependent Epitopes Are Frequently Targeted in Broad Neutralizing Antibody Responses during Human Immunodeficiency Virus Type 1 Infection. J Virol. 2012 Feb;86(4):2153-2164. Epub 2011 Dec 7. Abstract

Top